Retatrutide Meets Endpoints in Two More Phase 3 Trials
Eli Lilly reported that its investigational triple-receptor agonist retatrutide met its endpoints in two more Phase 3 obesity trials, TRIUMPH-2 and TRIUMPH-3. The company shared topline results in a July 23, 2026 investor release. Retatrutide is not approved by the FDA, and the figures below are as reported by the manufacturer.
What the two retatrutide Phase 3 trials reported
According to Lilly, TRIUMPH-2 studied adults with obesity or overweight and type 2 diabetes. The company reported body weight reductions of up to about 20.8% at 80 weeks at the highest dose evaluated. TRIUMPH-3 studied adults with severe obesity and established cardiovascular disease; Lilly reported weight reductions of up to about 22.6% at 80 weeks at the highest dose. The company also described changes in several cardiovascular risk markers in TRIUMPH-3. These are company-reported topline figures; full results would typically be presented at a scientific meeting or published in a peer-reviewed journal before independent review.
Regulatory timeline as stated by the company
Lilly stated that it plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027. A planned submission is a milestone in the development process and does not indicate approval. Retatrutide remains investigational, and any characterization of its efficacy or safety here reflects the company’s own reporting rather than an independent conclusion.
How this fits the broader picture
Retatrutide is described as a single molecule that acts on three receptors, part of a wider trend toward multi-receptor agonists in metabolic research. Earlier retatrutide data were reported separately; this update adds two more Phase 3 readouts to that program. As with any single company announcement, the topline nature of the data is worth keeping in mind until fuller results are available.
For background on this compound, see our retatrutide reference page and our earlier report on its Phase 3 diabetes results. More updates are on our news page.
